Fortrea Holdings (FTRE) Interest Expenses (2022 - 2023)
Fortrea Holdings' (FTRE) quarterly Interest Expenses came in at $9.3 million in Q2 2026, down 22.5% YoY from $12.0 million in Q2 2025, and down 60.26% on a QoQ basis from $23.4 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Interest Expenses (2022 - 2023) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Interest Expenses data on file, last reported at $9.3 million in Q2 2026.
- Quarterly Interest Expenses fell 22.5% year-over-year to $9.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.7 million (up 152.27% YoY) and the FY2025 annual result came in at $365.7 million, up 233.67% from the prior year.
- Interest Expenses declined to $9.3 million in Q2 2026, from $23.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $60.1 million in Q2 2023 to a low of -$46.9 million in Q4 2024.
- A 5-year average of $26.7 million and a median of $27.9 million in 2025 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 50000.0% in 2024, down 311.26% in 2024.
- Tracing FTRE's Interest Expenses over 5 years: stood at $50.5 million in 2022, then tumbled by 56.04% to $22.2 million in 2023, then plunged by 311.26% to -$46.9 million in 2024, then surged by 136.46% to $17.1 million in 2025, then slumped by 45.61% to $9.3 million in 2026.
- The last three Interest Expenses figures came in at $9.3 million (Q2 2026), $23.4 million (Q1 2026), and $17.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 34.50 Mn |
| Sep 30, 2023 | 34.60 Mn |
| Jun 30, 2023 | 700,000.00 |
| Dec 31, 2022 | 200,000.00 |